Scotiabank Initiates CPAY at Outperform as CEO Sells $90M

Corpay heads into September with a sharp divergence at its core: fresh analyst enthusiasm colliding with aggressive insider selling from the man who built the business.

The most immediate tension is at the top of the house. CEO and Chairman Ronald Clarke sold approximately $90 million worth of Corpay stock on August 24 and 25 — nearly 120,000 shares across multiple transactions, none filed under a pre-arranged 10b5-1 plan. Discretionary open-market sales of that size from a founder-CEO are among the highest-signal insider events in this data set. Clarke's net 90-day share disposal runs to roughly 218,000 shares worth over $90 million, and his disclosed stake has edged down to around 3.6% of shares. The institutional data registers his most recently reported holding at just under 2.35 million shares, down roughly 54,000 on the prior period. The sales do not invalidate the bull case, but they are a notable counterweight to the Street's increasingly constructive tone.

That Street tone has turned sharply bullish in recent weeks. Scotiabank initiated coverage on September 2 with a Sector Outperform rating and a $536 target — the highest on the board. Wolfe Research raised its target to $530 from $475 on August 25, maintaining Outperform. JP Morgan lifted to $470 on August 6 and kept its Overweight. The consensus mean target is around $455, roughly 12% above the current price of $404.81. RBC sits as the outlier at Sector Perform, most recently raising its target to $438. The bull case centres on continued momentum in Vehicle Payments and Corporate Payments, cross-border B2B flow growth, and a forward EPS trajectory that has been running well above prior-year estimates. Bears flag interest rate sensitivity, limited upside from the legacy Current Payments unit, and the question of whether a mid-teens earnings multiple already reflects the growth story — the trailing P/E runs near 13.5x with EV/EBITDA around 11.7x, both reasonable but not cheap for a payments franchise that has rallied 38% year-to-date.

Positioning in the lending market tells a calm story. Short interest is running at 3.6% of the free float — moderate for a payments name — and has actually declined around 5% on the week after building through mid-August. Borrow costs are low at 0.45%, down roughly 12% over the past month. Availability is extremely loose at 1,488%, meaning there are nearly 15 shares available to borrow for every share currently shorted. The ORTEX short score sits at 39.9, edging higher from a recent low of 39.4 but still firmly in neutral territory. This is not a name where lending dynamics or short pressure are driving the story.

Options positioning adds a modest wrinkle. The put/call ratio has risen to 0.11 from a run of extremely low readings in the 0.05–0.08 range through late August, though it remains well below the 20-day mean of 0.26 — about one standard deviation beneath average. That recent PCR pattern tells an interesting story: the ratio was sitting around 0.35 all through July and early August, then collapsed sharply after the August 5 earnings beat, suggesting call buyers flooded the market post-results. The slight pickup in the PCR this week, still historically low in absolute terms, may reflect some profit-taking on calls rather than fresh defensive positioning.

Institutional ownership is broadly stable, with BlackRock at 8.7%, Orbis at 8.2%, and Vanguard Capital at 6.9% as the three largest holders. Orbis filed a 13G/A in August showing a modest increase to 7.7% of class. FMR (Fidelity) filed a fresh 13G on August 6 disclosing a 5.5% stake. All filings are passive Schedule 13G — no activist 13D on the register. Positions are as last disclosed and subject to the usual caveat that holders can fall below 5% without further notification.

The next earnings event is not until November 4. Between now and then, the question shaping the stock is whether the Street's aggressive target upgrades — with four of the five most recent moves pointing higher — can hold up against the signal embedded in Clarke's discretionary $90 million exit at prices close to where the stock is trading today.